A compound capable of inducing exon 44 of the dystrophin gene to skip, which is (a) an oligonucleotide consisting of the nucleotide sequence shown in any one of SEQ ID NOs 30, 36, 37, 31, 32, 33, 38, 35, 34 and 39, wherein at least one of the sugars constituting the oligonucleotide is modified, and wherein said sugar is D-ribofuranose and at least one modification of said sugar is 2'-O,4'-C-alkylenation of the D-ribofuranose, or (b) a compound represented by any one of the general formula (I"), (II") and (III") or a pharmacologically acceptable salt thereof; wherein said general formulae are defined as follows: B T"1 -B M"1 -B B"1 (I") where B T" 1 is a group represented by any one of the following (1a") to (1m"): (1a") HO-, (1b") HO-Bt-, (1c") HO-Bt-Bt-, (1d") HO-Bt-Bt-Bt-, (1e") HO-Ba-Bt-Bt-Bt-, HO-Bt-Ba-Bt-Bt-Bt-, (1g") HO-Bg-Bt-Ba-Bt-Bt-Bt-, (1h") HO-Bt-Bg-Bt-Ba-Bt-Bt-Bt-, (1i") HO-Bt-Bt-Bg-Bt-Ba-Bt-Bt-Bt-, (1j") HO-Bt-Bt-Bt-Bg-Bt-Ba-Bt-Bt-Bt-, (1k") HO-Ba-Bt-Bt-Bt-Bg-Bt-Ba-Bt-Bt-Bt-, (1l") HO-Bc-Ba-Bt-Bt-Bt-Bg-Bt-Ba-Bt-Bt-Bt-, or (1m") HO-Bc-Bc-Ba-Bt-Bt-Bt-Bg-Bt-Ba-Bt-Bt-Bt-, B M"1 is a group represented by the following formula (1"): -Ba-Bg-Bc-Ba-Bt-Bg- (1") B B"1 is a group represented by any one of the following (101a") to (101m"): (101a") -CH 2 CH 2 OH, (101b") -Bt-CH 2 CH 2 OH, (101c") -Bt-Bt-CH 2 CH 2 OH, (101d") -Bt-Bt-Bc-CH 2 CH 2 OH, (101e") -Bt-Bt-Bc-Bc-CH 2 CH 2 OH, -Bt-Bt-Bc-Bc-Bc-CH 2 CH 2 OH, (101g") -Bt-Bt-Bc-Bc-Bc-Ba-CH 2 CH 2 OH, (101h") -Bt-Bt-Bc-Bc-Bc-Ba-Ba-CH 2 CH 2 OH, (101i") -Bt-Bt-Bc-Bc-Bc-Ba-Ba-Bt-CH 2 CH 2 OH, (101j") -Bt-Bt-Bc-Bc-Bc-Ba-Ba-Bt-Bt-CH 2 CH 2 OH, (101k") -Bt-Bt-Bc-Bc-Bc-Ba-Ba-Bt-Bt-Bc-CH 2 CH 2 OH, (101l") -Bt-Bt-Bc-Bc-Bc-Ba-Ba-Bt-Bt-Bc-Bt-CH 2 CH 2 OH, or (101m") -Bt-Bt-Bc-Bc-Bc-Ba-Ba-Bt-Bt-Bc-Bt-Bc-CH 2 CH 2 OH, where Bg is a group represented by the following formula or; Ba is a group represented by the following formula or; Bc is a group represented by the following formula or; and Bt is a group represented by the following formula or: where X is individually and independently a group represented by the following formula or: Y is individually and independently a hydrogen atom, a hydroxyl group or an alkoxy group with 1-6 carbon atoms; and Z is individually and independently a single bond or an alkylene group with 1-5 carbon atoms; provided that at least one of the nucleosides constituting the compound represented by formula (I") has 2'-O,4'-C-alkylene group; B T"2 -B M"2 -B B"2 (II") where B T"2 is a group represented by any one of the following (2a") to (2g"): (2a") HO-, (2b") HO-Bg-, (2c") HO-Bt-Bg-, (2d") HO-Ba-Bt-Bg-, (2e") HO-Bc-Ba-Bt-Bg-, HO-Bg-Bc-Ba-Bt-Bg-, or (2g") HO-Ba-Bg-Bc-Ba-Bt-Bg-, B M"2 is a group represented by the following formula (2"): -Bt-Bt-Bc-Bc-Bc-Ba-Ba-Bt-Bt-Bc-Bt-Bc- (2") B B"2 is a group represented by any one of the following (102a") to (102g"): (102a") -CH 2 CH 2 OH, (102b") -Ba-CH 2 CH 2 OH, (102c") -Ba-Bg-CH 2 CH 2 OH, (102d") -Ba-Bg-Bg-CH 2 CH 2 OH, (102e") -Ba-Bg-Bg-Ba-CH 2 CH 2 OH, -Ba-Bg-Bg-Ba-Ba-CH 2 CH 2 OH, or (102g") -Ba-Bg-Bg-Ba-Ba-Bt-CH 2 CH 2 OH, where Bg, Ba, Bt and Bc are as defined above; provided that at least one of the nucleosides constituting the compound represented by formula (II") has 2'-O,4'-C-alkylene group; B T"3 -B M"3 -B B"3 (III") where B T"3 is a group represented by any one of the following (3a") to (3m"): (3a") HO-, (3b") HO-Bc-, (3c") HO-Ba-Bc-, (3d") HO-Ba-Ba-Bc-, (3e") HO-Ba-Ba-Ba-Bc-, HO-Ba-Ba-Ba-Ba-Bc-, (3g") HO-Bg-Ba-Ba-Ba-Ba-Bc-, (3h") HO-Bt-Bg-Ba-Ba-Ba-Ba-Bc-, (3i") HO-Ba-Bt-Bg-Ba-Ba-Ba-Ba-Bc-, (3j") HO-Ba-Ba-Bt-Bg-Ba-Ba-Ba-Ba-Bc-, (3k") HO-Bt-Ba-Ba-Bt-Bg-Ba-Ba-Ba-Ba-Bc-, (3l") HO-Ba-Bt-Ba-Ba-Bt-Bg-Ba-Ba-Ba-Ba-Bc-, (3m") HO-Bc-Ba-Bt-Ba-Ba-Bt-Bg-Ba-Ba-Ba-Ba-Bc- B M"3 is a group represented by the following formula (3"): -Bg-Bc-Bc-Bg-Bc-Bc- (3") B B"3 is a group represented by any one of the following (103a") to (103m"): (103a") -CH 2 CH 2 OH, (103b") -Ba-CH 2 CH 2 OH, (103c") -Ba-Bt-CH 2 CH 2 OH, (103d") -Ba-Bt-Bt-CH 2 CH 2 OH, (103e") -Ba-Bt-Bt-Bt-CH 2 CH 2 OH, -Ba-Bt-Bt-Bt-Bc-CH 2 CH 2 OH, (103g") -Ba-Bt-Bt-Bt-Bc-Bt-CH 2 CH 2 OH, (103h") -Ba-Bt-Bt-Bt-Bc-Bt-Bc-CH 2 CH 2 OH, (103i") -Ba-Bt-Bt-Bt-Bc-Bt-Bc-Ba-CH 2 CH 2 OH, (103j") -Ba-Bt-Bt-Bt-Bc-Bt-Bc-Ba-Ba-CH 2 CH 2 OH, (103k") -Ba-Bt-Bt-Bt-Bc-Bt-Bc-Ba-Ba-Bc-CH 2 CH 2 OH, (103l") -Ba-Bt-Bt-Bt-Bc-Bt-Bc-Ba-Ba-Bc-Ba-CH 2 CH 2 OH, or (103m") -Ba-Bt-Bt-Bt-Bc-Bt-Bc-Ba-Ba-Bc-Ba-Bg-CH 2 CH 2 OH where Bg, Ba, Bt and Bc are as defined above; provided that at least one of the nucleosides constituting the compound represented by formula (III") has 2'-O,4'-C-alkylene group.